Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors

Background: Axitinib is a tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptor signaling and is approved for second-line treatment of advanced renal cell carcinoma (RCC). Although the occurrence of hypertension with axitinib use has been documented, it is unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Hiroshi, Ishida, Junichi, Akazawa, Hiroshi, Yagi, Hiroki, Saga-Kamo, Akiko, Umei, Masahiko, Matsuoka, Ryo, Liu, Qing, Matsunaga, Hiroshi, Maki, Hisataka, Sato, Yusuke, Kume, Haruki, Komuro, Issei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2021
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024013/
https://www.ncbi.nlm.nih.gov/pubmed/33842729
http://dx.doi.org/10.1253/circrep.CR-21-0008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024013/
https://www.ncbi.nlm.nih.gov/pubmed/33842729
http://dx.doi.org/10.1253/circrep.CR-21-0008

Ejemplares similares